261 studies on Insulin curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently curates 261 dated studies on Insulin. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.
This research is significant because it investigates a potential new benefit of tirzepatide beyond weight management and metabolic improvement: reducing breast cancer risk. Given the strong link between obesity and br…
This study is significant because it could elucidate the precise role of IGF-1 in the pathogenesis of vitiligo, specifically its interaction with oxidative stress. Understanding this mechanism could open new avenues f…
Despite its termination, this study highlights the ongoing effort to understand and optimize treatments for Primary IGF-1 Deficiency, a condition causing significant growth failure in children. The intent was to gathe…
This study highlights the potential for IDegLira to significantly improve the quality of life for very old patients with Type 2 Diabetes by streamlining their treatment. Simplifying medication regimens can enhance adh…
Oral semaglutide could offer a safer, more effective, and convenient alternative to insulin for managing post-transplant hyperglycemia, potentially mitigating risks like hypoglycemia and weight gain in a highly vulner…
This review provides crucial, actionable guidance that can significantly enhance patient safety and reduce perioperative complications for a rapidly expanding patient population. By differentiating the management stra…
While the specific, detailed results from this completed Phase 2 clinical trial (NCT01777542) are not included in the provided record, the study's primary objective was to evaluate the efficacy and safety of recombina…
This Phase 2 trial represents a significant step in exploring targeted treatments for Phelan-McDermid Syndrome, a condition with limited therapeutic options. If IGF-1 proves safe and effective in subsequent studies, i…
While specific quantitative results are not detailed in this summary, the study was designed to rigorously evaluate the efficacy of Liraglutide in a challenging patient population. The primary objective was to determi…
This research is significant because it addresses a critical health disparity, focusing on Mexican American women who are at elevated risk for type 2 diabetes. Improving beta cell function is a direct strategy to halt…
If successful, this trial could establish **dietary interventions as a valuable adjunctive strategy for managing acromegaly**, potentially improving hormonal control and patient quality of life beyond current pharmaco…
If Liraglutide or Metformin were found to positively influence the telomere-telomerase system or Par-4 in Type 2 Diabetes patients, it would provide novel insights into their mechanisms beyond glucose control. This co…
This study is significant because it provides valuable real-world data on the long-term effectiveness of Xultophy® in a diverse patient population, complementing controlled clinical trial findings. Understanding how a…
This review represents a conceptual shift in T2D management, proposing that cognitive preservation should become an explicit therapeutic objective, integrated with metabolic control. The identification of existing glu…
This research is significant because it directly addresses a critical unmet need for treatments that can improve connective tissue strength in Ehlers-Danlos Syndrome. If IGF-I proves effective in stimulating collagen …
The concept of continuous subcutaneous hydrocortisone infusion holds significant promise for patients with Addison's Disease, particularly those with co-existing Type 1 Diabetes, by potentially mimicking the body's na…
PCOS is a complex condition with significant unmet needs, particularly for obese and infertile women who struggle with its multifaceted symptoms. If liraglutide demonstrates superior or even comparable efficacy to met…
This foundational Phase 1 study was critical in establishing the initial safety and pharmacokinetic profile of liraglutide, a drug that later became a cornerstone in the treatment of Type 2 Diabetes and obesity. The p…
This study is highly significant because it could establish Tirzepatide as more than just a powerful glucose-lowering agent, potentially offering a crucial benefit in addressing diabetes-related cognitive impairment. …
The findings from this study, once published, will be crucial for understanding the full therapeutic potential of incretin-based therapies beyond current GLP-1 receptor agonists. If the combined GIP and GLP-1 activati…
Given the significant public health burden of Cannabis Use Disorder and the scarcity of effective pharmacological interventions, a successful outcome from this trial could be transformative. Tirzepatide, a dual GLP-1 …
The termination of this trial highlights the significant challenges in developing and testing combination therapies for complex conditions like IGF-1 deficiency and short stature. While this specific study did not yie…
Sandostatin LAR is a well-established treatment for acromegaly, and this study aimed to refine our understanding of its comprehensive benefits beyond just hormone suppression. Demonstrating clear improvements in metab…
This study is significant because it explores the practical application of lanreotide Autogel 120 mg at extended dosing intervals, potentially offering a more convenient and less burdensome treatment schedule for pati…
The successful completion of this Phase 3 trial is a significant step towards developing an effective treatment for primary IGF-1 deficiency, a condition with limited therapeutic options. rhIGF-1 (mecasermin) holds su…
This pioneering single-patient study represents an early, crucial exploration into a novel therapeutic approach for a complex and rare genetic disease. Targeting low IGF-1 levels in Werner's Syndrome patients with ost…
This study is crucial because it could establish continuous glucose monitoring (CGM) as a superior standard of care for managing hyperglycemia in hospitalized patients, potentially reducing inflammation and improving …
Understanding Liraglutide's direct effects on inflammation could significantly broaden its therapeutic implications beyond glycemic control and weight management. If Liraglutide can effectively reduce adipose tissue i…
If liraglutide were found to be effective and safe as an add-on therapy for Type 1 Diabetes, it could represent a significant advancement in managing this complex condition. Such a finding could potentially lead to im…
While this specific study did not yield results, the underlying hypothesis of combining GLP-1 agonists with increased Non-exercise Activity Thermogenesis (NEAT) remains highly relevant for optimizing Type 2 Diabetes m…
The concept behind this trial was significant: liraglutide, a GLP-1 receptor agonist, has shown potential in preserving beta-cell function and promoting their survival, which could theoretically enhance the success an…
If successful, this novel approach could offer a significant advancement for patients with Type 2 Diabetes who are dependent on insulin. Reducing or eliminating the need for insulin injections would substantially impr…
The daily burden of carbohydrate counting remains a significant challenge for individuals with Type 1 Diabetes, even with the most advanced closed-loop systems. If weekly Semaglutide proves effective in reducing this …
The findings from this trial, once fully published, could significantly impact clinical guidelines for managing Type 2 Diabetes in the critical post-hospitalization period. Identifying effective non-insulin options li…
Effective management of Type 2 Diabetes often requires combination therapies to achieve optimal glycemic control and address comorbidities like obesity. CagriSema combines semaglutide (a potent GLP-1 receptor agonist)…
Free, no account — handy when you're working with Insulin.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account